ClinicalTrials.Veeva

Menu

The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial (PAPPI)

C

Copenhagen University Hospital, Rigshospitalet

Status

Enrolling

Conditions

Aortic Valve Stenosis

Treatments

Drug: Beta-lactam antibiotic with spectrum for Enterococcus faecalis
Drug: Cephalosporin

Study type

Interventional

Funder types

Other

Identifiers

NCT07442357
p-2025-19665

Details and patient eligibility

About

The study is a prospective, crossover, cluster randomized trial in patients undergoing transcatheter aortic valve implantation (TAVI). The study tests whether cephalosporin plus beta-lactam antibiotic with spectrum for Enterococcus faecalis as per procedural prophylaxis is superior to cephalosporin alone in reducing the composite outcome of bacteremia or death at 6 months post-TAVI.

Full description

The PAPPI trial is designed as a prospective, crossover, unblinded, cluster randomized trial. The study includes all TAVI centers in Denmark. Each center will be included for either single dose cephalosporin (1st, 2nd or 3rd generation) plus a beta-lactam antibiotic with spectrum for Enterococcus faecalis (e.g. ampicillin 2g) or single dose of a cephalosporin (1st, 2nd or 3rd generation) as antibiotic prophylaxis in relation to TAVI. The antibiotic(s) will be given as a single dose intravenously per-procedural. Patients will be followed from date of TAVI procedure until 6 months post procedure.

The primary outcome of the PAPPI trial will be a composite of the following components within 6 months post TAVI:

  • Bacteremia (excluding all enterobacterales)
  • Death

Secondary outcomes will be each separate component of the primary outcome and will be ana-lyzed separately as time-to-first event analysis. Additional secondary outcomes will be;

  • Bacteremia (excluding all enterobacterales)
  • Acute kidney failure
  • Death
  • Length of hospital stay
  • Days-out-of-hospital from TAVI to 6 months

Enrollment

1,986 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All patients > 18 years of age undergoing TAVI at sites in Denmark

Exclusion criteria

  • Patients who do not want to participate and have chosen to "opt-out" of the trial

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

1,986 participants in 2 patient groups

Cephalosporin (1st, 2nd or 3rd generation) + betalactam with spectrum for Enterococcus faecalis
Active Comparator group
Description:
Cephalosporin (1st, 2nd or 3rd generation) + betalactam with spectrum for Enterococcus faecalis
Treatment:
Drug: Cephalosporin
Drug: Beta-lactam antibiotic with spectrum for Enterococcus faecalis
Cephalosporin (1st, 2nd, 3rd generation)
Active Comparator group
Description:
Cephalosporin (1st, 2nd, 3rd generation)
Treatment:
Drug: Cephalosporin

Trial contacts and locations

5

Loading...

Central trial contact

Emil L Fosbøl, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems